A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice

A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice

Antisense RNA technology is a strategy for the treatment of Duchenne muscular dystrophy (DMD), a progressive and universally fatal X-linked neuromuscular disease caused by frameshift mutations in the gene encoding dystrophin. Phosphorodiamidate morpholino oligomers (PMOs) are an antisense RNA platfo...

Full description

Bibliographic Details
Main Authors:	Li Gan, Leslie C.L. Wu, Jenna A. Wood, Monica Yao, Chris M. Treleaven, Nelsa L. Estrella, Bruce M. Wentworth, Gunnar J. Hanson, Marco A. Passini
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Molecular Therapy: Nucleic Acids
Subjects:	MT: oligonucleotides: therapies and applications Duchenne muscular dystrophy dystrophin exon-skipping therapy neuromuscular disease peptide-conjugated phosphorodiamidate morpholino oligomer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253122002189

Similar Items

In Vitro Validation of Phosphorodiamidate Morpholino Oligomers
by: May T. Aung-Htut, et al.
Published: (2019-08-01)

Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience
by: Roshmi RR, et al.
Published: (2021-12-01)

Eteplirsen in the treatment of Duchenne muscular dystrophy
by: Lim KRQ, et al.
Published: (2017-02-01)

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
by: Yusuke Echigoya, et al.
Published: (2018-12-01)

Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics
by: Farkhad Maksudov, et al.
Published: (2023-03-01)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
by: Alberto Malerba, et al.
Published: (2012-01-01)

Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds
by: Yuchen Nan, et al.
Published: (2018-04-01)

MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice
by: Ning Ran, et al.
Published: (2021-02-01)

A <i>Dystrophin</i> Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping
by: Yusuke Echigoya, et al.
Published: (2021-12-01)

Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2′-O-Methyl Mixmer Antisense Oligonucleotide
by: Suxiang Chen, et al.
Published: (2016-11-01)

Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
by: Derek W. Wang, et al.
Published: (2018-06-01)

Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review
by: Zorica Nakevska, et al.
Published: (2023-06-01)

Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice
by: Xianjun Gao, et al.
Published: (2015-01-01)

Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
by: Liubov V. Gushchina, et al.
Published: (2022-12-01)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
by: Corinne Betts, et al.
Published: (2012-01-01)

Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
by: Yusuke Echigoya, et al.
Published: (2015-01-01)

Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry
by: Sibasish Paul, et al.
Published: (2023-07-01)

Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
by: Kane L Greer, et al.
Published: (2014-01-01)

The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides
by: Miklós Bege, et al.
Published: (2022-07-01)

Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice
by: Limin Cao, et al.
Published: (2016-01-01)

Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene
by: Kane Greer, et al.
Published: (2020-06-01)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
by: Remko Goossens, et al.
Published: (2023-12-01)

Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of <i>SMN2</i> in SMA Type I Fibroblasts
by: Jarichad Toosaranont, et al.
Published: (2022-04-01)

Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections
by: Sina Bavari, et al.
Published: (2012-11-01)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
by: HaiFang Yin, et al.
Published: (2013-01-01)

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy
by: Nguyen Q, et al.
Published: (2019-07-01)

Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice
by: Amel Saoudi, et al.
Published: (2023-06-01)

Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide
by: Umme Sabrina Haque, et al.
Published: (2023-10-01)

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
by: Fernanda Fortunato, et al.
Published: (2021-02-01)

Electrical impedance myography detects dystrophin-related muscle changes in mdx mice
by: Tetsuaki Hiyoshi, et al.
Published: (2023-11-01)

Networking to Optimize <i>Dmd</i> exon 53 Skipping in the Brain of <i>mdx52</i> Mouse Model
by: Mathilde Doisy, et al.
Published: (2023-12-01)

Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies
by: Elisabeth Le Rumeur
Published: (2015-07-01)

Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse
by: Glenn Dallérac, et al.
Published: (2011-09-01)

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
by: Theodora Markati, et al.
Published: (2021-11-01)

Clinical, immunohistochemical, and genetic characterization of splice-altering biallelic DES variants: Therapeutic implications
by: Janelle Geist Hauserman, et al.
Published: (2024-04-01)

Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
by: Nicholas P Clayton, et al.
Published: (2014-01-01)

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
by: Quynh Nguyen, et al.
Published: (2017-10-01)

Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model
by: Flavien Bizot, et al.
Published: (2023-02-01)

Targeted Exon Skipping to Address “Leaky” Mutations in the Dystrophin Gene
by: Sue Fletcher, et al.
Published: (2012-01-01)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
by: Flavien Bizot, et al.
Published: (2022-12-01)